Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Licensed B cells induce immunotolerance

No. 37c | 03/08/2015

In order to protect organs against attacks by the immune system, the body has developed complex protective mechanisms. For instance, T cells that are directed against the body's own proteins are selected out in the thymus. Scientists at the Ludwig-Maximilian-University (LMU) in Munich and the German Cancer Research Center have now discovered that B cells migrating into the thymus also contribute to immunotolerance. On entering the thymus, they alter their molecular makeup and become "licensed" to induce tolerance.

© Sheena Pinto,DKFZ

The body's own immune system can easily become a threat: When immune cells turn against the body's own tissues, they provoke autoimmune diseases that may even end in death. The body has therefore built up solid defenses against such lapses. The immune system's T cells are carefully regulated for this purpose. This takes place in the thymus, a small, gland-like organ behind the sternum. This is where the T cell precursors that recognize endogenous proteins by means of their antenna-like receptors are immediately selected out. Immunologists call this process "negative selection", and the result is "central tolerance".

Bruno Kyewski, an immunologist from the German Cancer Research Center, is an expert in T cell tolerance. Some years ago, he elucidated processes in the thymus that are instrumental in the selection of autoreactive T cells. But there's a trick involved: whereas all the body's other cells produce only those proteins that are needed in a particular tissue, thymus cells (medullary thymic epithelial cells) may produce an extremely broad spectrum of proteins. They act as a kind of "showroom" for all endogenous proteins.

A T cell precursor maturing in the thymus whose receptor happens to fit one of these displayed proteins is eliminated immediately. The regulator protein Aire plays a key role in this process. It is this transcription factor that enables the thymus cells to produce their full arsenal of endogenous proteins.

Together with Ludger Klein and his colleagues from LMU Munich, Bruno Kyewski has now discovered that B cells migrating into the thymus also express Aire and are thus theoretically able to induce tolerance. B cells are the immune system's second major arsenal. The teams from Munich and Heidelberg discovered that the B cells in the thymus change their molecular makeup at the same time as they express Aire and receive a "tolerance license", as it were.

The scientists asked themselves whether these tolerance-licensed B cells can actually contribute to the elimination of autoreactive T cells. Their approach was to inject the gene for the viral protein hemagglutinin under regulation by the transcription factor Aire into the B cells of mice. If the animals' B cells received their "tolerance license" in the thymus, the T cell precursors directed against hemagglutinin were indeed eliminated.

"Reliable immunotolerance is important for an entire lifetime. The body has to ensure that all self-antigens are protected against T cell attacks," explains Bruno Kyewski. The reason why B cells have to play an important role is that their repertoire of self-antigens in the lymph nodes can change in the course of an inflammatory immune response. These newly created self-antigens could trigger an autoimmune reaction. The researchers speculate that B cells contribute to inducing tolerance in order to protect themselves against T cell attacks on the newly created self-antigens.

Tomoyoshi Yamano, Jelena Nedjic, Maria Hinterberger, Madlen Steinert, Sandra Koser, Sheena Pinto, Norbert Gerdes, Esther Lutgens, Naozumi Ishimaru, Meinrad Busslinger, Benedikt Brors, Bruno Kyewski, and Ludger Klein: Thymic B Cells Are Licensed to Present Self Antigens for Central T Cell Tolerance Induction. Immunity 2015, DOI: 10.1016/j.immuni.2015.05.013

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS